Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00003131 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse (NCT00003131)

Trial Description
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. This is a Phase II trial to study the effectiveness of the antibody-drug conjugate gemtuzumab ozogamicin (also know as CMA-676 / Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) in treating patients with acute myeloid leukemia in first relapse.

This trial is sponsored by Pfizer. [1]

Study Data

  • Condition: Leukemia
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 55
  • Start: February 1997
  • Completion: February 2002
  • Last verified: August 2012

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 23, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar